Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721577 | 0.89 | FLT3 (0.48) | FLT3EPHX2KDRCNR1 | |
| SCHEMBL4724126 | 0.86 | CNR1 (0.47) | FLT3NPC1RAB9ACNR1MAPT | |
| SCHEMBL4723103 | 0.86 | CNR1 (0.55) | FLT3KDRRAB9ACNR1MAPT | |
| SCHEMBL4720666 | 0.84 | BLM (0.44) | FLT3KDRCNR1MAPT | |
| SCHEMBL4721629 | 0.83 | FLT3 (0.49) | FLT3KDRRAB9AMAPT | |
| SCHEMBL4724468 | 0.82 | MAPT (0.46) | EPHX2NPC1RAB9ACNR1MAPT | |
| SCHEMBL1323863 | 0.82 | EPHX2 (0.56) | FLT3EPHX2KDRNPC1ABL1 | |
| SCHEMBL4725018 | 0.82 | KDR (0.44) | KDRNPC1RAB9ACNR1MAPT | |
| SCHEMBL4721735 | 0.81 | FLT3 (0.51) | FLT3NPC1RAB9AMAPT | |
| SCHEMBL4816720 | 0.81 | FLT3 (0.41) | FLT3KDRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912988-B1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA SA (FR) | 2014-04-16 | — | — | EP | claimed |
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-07-31 | — | — | US | claimed |
| EP-1912988-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | Aventis Pharma S.A. (FR) | 2008-04-23 | — | — | EP | claimed |
| WO-2007017577-A1 | 7-SUBSTITUTED AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PRODUCTION METHOD AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2007-02-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182844-A1 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof | PRMT7, PRKACA, PRKX | FLT3 525/4885EPHX2 2677/4885IGF1R 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.